Context: Luteal progesterone is fundamental for reproduction but the molecular regulation of 27 the corpus luteum (CL) in women remains unclear. Galectin-1 and galectin-3 bind to the sugar 28 chains on cells to control key biological processes including cell function and fate. LGALS3 in vivo (P<0.05) and in vitro (P<0.001). There was an inverse correlation between 41 the expression of ST6GAL1 and HSD3B1 (P<0.01), and a distinct cellular relationship among 42 2,6-sialylation, 3-HSD, and galectin expression. Conclusions: Galectin-1 is a luteotrophic factor whose binding is inhibited by 2,6-sialylation 44 in the human CL during luteolysis. ST6GAL1 and galectin-3 expression is increased during 45 luteolysis and associated with a loss of progesterone synthesis. Luteotrophic hormones 46 differentially regulate galectin-1 and galectin-3/2,6-sialylation in granulosa lutein cells, 47 suggesting a novel galectin switch regulated by luteotrophic stimuli during luteolysis and luteal 48 rescue. 49 50 3
6
After removal of oocytes from the follicular aspirates obtained from the patients undergoing 126 assisted conception, the remaining fluid was centrifuged at 1,500 rpm for 10 min, and cells were 127 re-suspended in culture medium (DMEM/Ham's F-12 containing 2 mM L-glutamine, 10 128 unit/mL penicillin, 0.1 mg/mL streptomycin, 2.5 μg/mL amphotericin B, and 1× concentration 129 of ITS-X). The cell suspension was layered over 45% Percoll/culture medium mixture and 130 centrifuged at 1,200 rpm for 30 min to pellet blood cells.
LGCs, visible in the interface, were 131 collected by a pipette and washed with Dulbecco's phosphate buffered saline with MgCl 2 and 132
CaCl 2 three times. One hundred-thousand viable cells were seeded on Matrigel-coated 24 well 133 plates and cultured with 1 mL of culture medium at 37°C in 5% CO 2 in air. The culture 134 medium was changed every two days, and cells were treated on day 6 with either 100 ng/mL 135 hCG or 10 ng/mL PGE 2 for 24 h. For long-term treatment with hCG, cells were treated with 136 100 ng/mL hCG for 4 days from day 6 and collected daily from day 7 until day 11. For hCG 137 withdrawal experiment, LGCs were treated with 1 ng/mL hCG from the next day of plating for 138 continuous 6 days, changed to the media without hCG on day 7, and collected daily until day 11. 139 Each experiment was repeated at least three times. 140
141

RNA extraction and reverse transcription (RT) 142
The CLs used for a quantitative gene expression analysis were classified as early-luteal (n=7), 143 mid-luteal (n=8), late-luteal (n=7), menstrual phases (n=3), and rescued by hCG injection (n=4). 144 Total RNA was purified from the frozen tissues of human CL or cultured LGCs using RNeasy 145
Mini Kit (Qiagen Ltd., Crawley, UK) following the manufacturer's protocol. RNA (200 ng) 146 was used to prepare cDNA using the TaqMan Reverse Transcription regents (Applied 147 Biosystems, Foster City, CA). The sequences of the primer sets used for this study are listed in Table 1 . Primers were 151 pre-validated by standard PCR and generating standard curves in qPCR. Each reaction buffer 152 contained 5.0 µL 2×PowerSYBR ® Green PCR Master Mix (Applied Biosystems), 0.5 µL primer 153 pair (5 µM), 3.5 µL of nuclease free H 2 O, and 1.0 µL cDNA, and each reaction was conducted 154 in duplicate. The qPCR cycling program consisted of a denaturing step (95°C for 10 min), 155 annealing and extension step (95°C for 15 sec and 60°C for 1 min repeated for 40 cycles), and a 156 dissociation step (95°C, 60°C, and 95°C for 15 sec each). The reactions were carried out using 157 a 7900 Sequence Detection System (Applied Biosystems). The relative expression levels of 158 each target gene to glucose-6-phosphate dehydrogenase (G6PD) as a house keeping gene, as 159 previously validated using geNorm analysis (Primerdesign Ltd, Southampton, UK), were 160 quantified using the Δ Ct or ΔΔ Ct methods. All statistical analyses were performed using 161 un-paired t-tests or one-way ANOVA, after testing for normality, using Graphpad prism 6 162 software (Graphpad Software Inc., San Diego, CA, USA) and P<0.05 was regarded as 163
significant. 164 165
Immunohistochemistry & lectin histochemistry 166 Fixed human CL tissues at early-luteal (n=20), mid-luteal (n=34), late-luteal (n=22), and 167 menstrual phases (n=5) were used for histochemical analysis. The tissues were dehydrated 168 through ethanol and embedded into paraffin according to the conventional method. The 169 sections, at 5 m thickness, were de-waxed and washed in phosphate-buffered saline (PBS). 170 Subsequently the sections were incubated with 3% hydrogen peroxide for 20 min and 171
Avidin/Biotin blocking solution (Vector Laboratories Inc., Burlingame, CA) for 15 min for each 172 reagent. Then the sections were incubated with normal rabbit or goat serum for 60 min at 173 room temperature. They were incubated with goat anti-human galectin- 
Results
201
Expression and regulation of galectin-1 in the human CL 202 We first assessed whether galectin-1 was expressed in the human CL.
LGALS1 was expressed 203 in the CL at all luteal phases ( Figure 1A ). It could be localized by immunohistochemistry to 204 the cytoplasm of granulosa lutein cells throughout the luteal phase ( Figure 1B-E Figure 1B) . 207 We next examined the effect of simulated early pregnancy using incremental hCG 208 injections for 5 to 8 days in vivo. Luteal rescue with hCG did not alter the expression of 209
LGALS1 in the CL ( Figure 1F ). However, luteotrophic hormones could acutely increase 210
LGALS1 expression in steroidogenic cells: both hCG ( Figure 1G ; P<0.001) and PGE 2 ( Figure  211 1H; P<0.001) increased LGALS1 expression in human LGCs. In addition, the ability of hCG 212 to augment LGALS1 decreased with duration of exposure in vitro ( Figure 1I ), paralleling what is 213 seen in vivo ( Figure 1F ). Overall galectin-1 is expressed in luteal steroidogenic cells and is 214 acutely increased by molecules that promote normal luteal function. 215
216
Expression and regulation of galectin-3 in the human CL 217 We next addressed whether galectin-3 was expressed in the human CL. In contrast to LGALS1, 218 LGALS3 was low in the early-and mid-luteal CL ( Figure 2A ). Its expression during the 219 functional luteal phase was maximal in the late-luteal phase (Figure 2A ; P<0.05). However 220 there was marked LGALS3 expression in the non-functional CL collected during menstruation 221 (Figure 2A ; P<0.001). Galectin-3 immunoreactivity was mainly found in stellate or 222 spindle-shaped cells scattered in the CL parenchyma (arrows in Figure 2B ). These were 223 identified as infiltrating macrophages and were more marked in the CL at late-luteal phase 224 ( Figure 2C ). Thus the increasing LGALS3 as the functional CL ages may reflect an increased 225 10 number of galectin-3-positive macrophages. 226
While galectin-3 immunoreactivity in granulosa lutein cells was faint in the functional CL 227 ( Figure 2B and 2C), this was not the case in a regressing CL from the previous cycle. Unlike 228 the healthy CL at early-luteal phase which contained abundant 3-HSD but does not express 229 galectin-3 ("new" in Figure 2D and 2E), the regressing CL with minimal 3-HSD displayed 230 marked galectin-3 immunostaining ("old" in Figure 2D Thus as the human CL undergoes luteolysis there seems to be a switch of the major galectin 243 subtype in steroidogenic cells from galectin-1 to galectin-3. As the ligands for galectins are 244 glycoconjugates, we next examined the effect of luteotrophic molecules on glycoconjugates on 245 lutein cells. Galectins possess a high affinity for LacNAc structure, and 2,6-sialylation of its 246 terminal galactose, catalyzed by ST6GAL1 sialyltransferase, inhibits galectin-1 action but does 247 not influence that of galectin-3 ( Figure 3A ). We therefore examined the expression and 248 regulation of ST6GAL1. Overall luteotrophic signals suppress ST6GAL1 to promote galectin-1 binding while loss of 259 luteotrophic signals increase ST6GAL1 and promote galectin-3 binding to glycoconjugates. 260 The increase of ST6GAL1 in the human CL as it ages parallels the reduction in HSD3B1. 261 
262
Intimate relationship of 2,6-sialylation and loss of progesterone production in luteal cells 263 We next examined the temporal association between increased ST6GAL1 activity and the loss 264 of 3-HSD in the human CL. Serial sections of human CL were stained with an 2,6-sialic 265 acid-recognizing plant lectin (SNA) and for 3-HSD. Intense SNA reaction was found in 266 endothelial cells (arrows in Figure 3H and 3J) while most numbers of granulosa lutein cells 267 were negative for the SNA reaction ( Figure 3H and 3J) . However, some cells contained 268 2,6-sialic acids in the cytoplasm or plasma membrane and these cells showed faint or negative 269 immunoreactivity for 3-HSD (asterisks in Figure 3H-K) . 2,6-sialylation, loss of 3-HSD and galectin expression in serial sections (Figure 4A-D) . 274 Granulosa lutein cells with residual 3-HSD ("1" in Figure 4A ) did not express 2,6-sialic acids12 ("1" in Figure 4B ) while they expressed galectin-1 ("1" in Figure 4C ) and did not express 276 galectin-3 ("1" in Figure 4C ). Neighboring lutein cells not expressing 3-HSD ("2" in Figure  277 4A) contained 2,6-sialic acids ("2" in Figure 4B ) and less galectin-1 ("2" in Figure 4C ) and 278 more galectin-3 ("2" in Figure 4D ). Certain areas were occupied with pyknotic cells with 279 moderate 3-HSD ("3" in Figure 4A ) but increased 2,6-sialic acids ("3" in Figure 4B ) and 280 without galectins ("3" in Figure 4C and 4D ). This suggests a co-ordinated relationship 281 between galectins, 2,6-sialyation, and loss of 3-HSD during luteolysis ( Figure 4E) . 282 Differential staining patterns for galectins and 2,6-sialic acids were tightly correlated to the 283 functional and structural status of granulosa lutein cells during luteolysis. This study revealed for the first time the differential expression and localization of galectin-1 302 and galectin-3 in the human CL throughout menstrual cycle. Galectin-1 was predominantly 303 expressed in the human CL and its expression in luteal steroidogenic cells in vitro was 304 up-regulated by luteotrophic molecules (hCG and PGE 2 ), suggesting an important role of 305 galectin-1 in luteotrophic process. On the other hand, galectin-3 was dramatically increased in 306 the regressing CL and its expression was suppressed by hCG and PGE 2 in luteal cells. 307
Galectin-3 expression was intense in luteal cells without 3-HSD immunoreactivity in the 308 regressing human CL, and we previously showed the concomitant expression of galectin-3 and 309 a progesterone degradation enzyme in the mouse CL (4). Thus, there could be an intimate 310 relation between galectin-3 expression and the cessation of progesterone synthesis in the CL 311 during luteolysis. 312 We also revealed for the first time that hCG and PGE 2 significantly down-regulate 313 ST6GAL1 which, like galectin-3, is intensely expressed in the regressing CL at late-luteal and 314 menstrual phases. This enzyme catalyzes 2,6-sialylation of the terminal galactose on 315 glycoconjugates to interfere the binding of galectin-1, therefore we propose here an existence of 316 galectin switch regulated by luteotrophic hCG and PGE 2 via 2,6-sialylation of glycoconjugates. 317 This highlights the importance of the interaction between galectin-1 and glycoconjugates in 318 luteal cells in the mechanism of luteal rescue regulated by hCG, and a contribution of galectin-3 319 and 2,6-sialic acids to the regulation of luteolysis. 320 Although luteal cells in the functional CL of mice do not express any galectins, human 321 luteal cells in the functional CL are characterized by rich existence of galectin-1. As 322 mentioned above, galectin-1 in human LGCs was significantly up-regulated by hCG and PGE 2 , 323 suggesting its luteotrophic contribution in the human CL.
As galectins bind to 324 glycoconjugates, the interaction between galectin-1 and sugar chains on cell surface molecules lutein cells may increase in number under low luteotrophic stimuli, and escape from apoptosis 377 and degenerate slowly. In support of this idea, the old 3-HSD-negative CL consisted with 378 galectin-3-positive granulosa lutein cells remained in the ovary over the menstrual cycle as 379 shown in Figure 2D and 2E. 380
In conclusion, we propose here a possible contribution of an interaction between galectin-1 381 and glycoconjugates in the regulation of luteal function, and a possible role of galectin-3 and 382 2,6-sialic acids in luteolysis. Accumulation of 2,6-sialic acids and galectin-3 in luteal cells 383 may inhibit galectin-1 binding to its ligands and contribute to luteolysis, resulting in 384 degeneration of luteal cells. The parallels with the rodent CL highlight the utility of selective 385 knock-out models to further assess the molecular roles of galectins in luteal function. 386 Although detailed experiments using knock-out or knock-down models will to reveal the exact 387 function of galectins in the CL, it is likely that galectin and sugar chain interactions have 388 fundamental roles in the regulation of luteal function. LGCs. Human CL predominantly expresses LGALS1 mRNA throughout the menstrual cycle 503 (A). Immunohistochemical analysis demonstrates an intense immunoreactivity for galectin-1 504 in the cytoplasm of glanulosa lutein cells at mid-luteal (ML; B) and late-luteal phases (LL; C). 505 Fibroblasts distributed in central clot are also immunostained for galectin-1 (arrowheads in B) , 506 while endothelial cells are negative in the reaction (arrows in D). The expression of LGALS1 507
is not altered by hCG in vivo (F) while acutely increased by hCG and PGE 2 in vitro (G, H). 508 LGALS1 expression does not alter with longer hCG exposure in vitro (I). E: control section in LGCs. The expression of LGALS3 mRNA is low in EL and ML phases but elevates at LL and 515 menstrual phases as revealed by qPCR (A). Galectin-3 immunoreactivity is observed in 516 scattered cells, being identifiable as infiltrating macrophages (arrows in B) in ML phase. 
